INCY

SEC source: 0001209191-17-004583 · doc4.xml · derivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,986

Underlying: Common Stock · 17,986 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004577 · doc4.xml · derivative · entry 3

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 879

Underlying: Common Stock · 879 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004577 · doc4.xml · derivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,986

Underlying: Common Stock · 17,986 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004577 · doc4.xml · derivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004570 · doc4.xml · derivative · entry 4

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 879

Underlying: Common Stock · 879 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004570 · doc4.xml · derivative · entry 3

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,906

Underlying: Common Stock · 4,906 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004570 · doc4.xml · derivative · entry 2

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286

Underlying: Common Stock · 286 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004570 · doc4.xml · derivative · entry 1

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,229

Underlying: Common Stock · 5,229 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004563 · doc4.xml · derivative · entry 3

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 879

Underlying: Common Stock · 879 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004563 · doc4.xml · derivative · entry 2

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,986

Underlying: Common Stock · 17,986 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004563 · doc4.xml · derivative · entry 1

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004557 · doc4.xml · derivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004555 · doc4.xml · derivative · entry 1

Siegel Eric H. · CIK 0001527573 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004550 · doc4.xml · derivative · entry 3

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 879

Underlying: Common Stock · 879 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004550 · doc4.xml · derivative · entry 2

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,986

Underlying: Common Stock · 17,986 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004550 · doc4.xml · derivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004542 · doc4.xml · derivative · entry 1

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004506 · doc4.xml · derivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,091

Underlying: Common Stock · 19,091 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-004496 · doc4.xml · derivative · entry 3

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 879

Underlying: Common Stock · 879 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004496 · doc4.xml · derivative · entry 2

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,446

Underlying: Common Stock · 93,446 shares

Expires 2027-01-16

F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021.

SEC source: 0001209191-17-004496 · doc4.xml · derivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,245

Underlying: Common Stock · 74,245 shares

Expires 2027-01-16

F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.

SEC source: 0001209191-17-003360 · doc4.xml · nonDerivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,185

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-16-157107 · doc4.xml · nonDerivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,712

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001209191-16-157105 · doc4.xml · nonDerivative · entry 1

BROOKE PAUL A · CIK 0001175940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,756

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001209191-16-157102 · doc4.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,069

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001638599-17-000024 · doc4_4439.xml · nonDerivative · entry 6

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 533,909

F4 · ownership.nature: 189 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors, LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F8 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 533,909 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 1,418 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares received previously from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 189 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-17-000024 · doc4_4439.xml · nonDerivative · entry 5

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 19,758,174

F4 · ownership.nature: 189 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors, LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F7 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 19,758,174 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 1,418 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares received previously from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 189 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-17-000024 · doc4_4439.xml · nonDerivative · entry 4

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,359,840

F4 · ownership.nature: 189 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors, LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F6 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 3,359,840 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 1,418 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares received previously from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 189 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001209191-16-150867 · doc4.xml · derivative · entry 5

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,317 shares

Expires 2018-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-16-150867 · doc4.xml · derivative · entry 4

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,683 shares

Expires 2018-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-16-150867 · doc4.xml · nonDerivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,248

F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents weighted average sale price. Actual sale prices ranged from $101.77- $104.60.

F3 · price: Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a security holder of the issuer detailed information regarding the price and number of shares sold within range indicated.

F4 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-16-150867 · doc4.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-150867 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-149366 · doc4.xml · nonDerivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,924

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-16-146758 · doc4.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,317

Underlying: Common Stock · 10,000 shares

Expires 2018-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-16-146758 · doc4.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,248

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-16-146758 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-145584 · doc4.xml · derivative · entry 3

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,709 shares

Expires 2020-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

SEC source: 0001209191-16-145584 · doc4.xml · nonDerivative · entry 2

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,601

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.

F3 · price: Represents weighted average sale price. Actual sale prices ranged from $95.24 - $97.00

F4 · balance_after: Includes an aggregate of 27,496 shares of common stock issuable to previously reported restricted stock units that have not vested.

SEC source: 0001209191-16-145584 · doc4.xml · nonDerivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,310

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-145577 · doc4.xml · derivative · entry 5

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,422

Underlying: Common Stock · 21,796 shares

Expires 2021-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years

SEC source: 0001209191-16-145577 · doc4.xml · derivative · entry 4

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,784

Underlying: Common Stock · 2,408 shares

Expires 2021-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years

SEC source: 0001209191-16-145577 · doc4.xml · nonDerivative · entry 3

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,187

F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-16-145577 · doc4.xml · nonDerivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-145577 · doc4.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,595

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001638599-16-001442 · doc4_4251.xml · nonDerivative · entry 6

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 533,720

F4 · ownership.nature: 201 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors, LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F8 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 533,720 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 1,229 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares received previously from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 201 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-16-001442 · doc4_4251.xml · nonDerivative · entry 5

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 19,757,985

F4 · ownership.nature: 201 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors, LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F7 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 19,757,985 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 1,229 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares received previously from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 201 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001638599-16-001442 · doc4_4251.xml · nonDerivative · entry 4

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,359,651

F4 · ownership.nature: 201 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors, LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities issued in lieu of director fees. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F6 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 3,359,651 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 1,229 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 75,000 shares received previously from exercise of 75,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: The 201 shares are reported for each of the Funds as each has an indirect pecuniary interest.

SEC source: 0001209191-16-144329 · doc4.xml · nonDerivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,550

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

SEC source: 0001209191-16-144320 · doc4.xml · nonDerivative · entry 1

BROOKE PAUL A · CIK 0001175940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,520

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.